WebMar 28, 2024 · We are currently investigating our lead candidate CT1812 in clinical programs in Alzheimer’s disease, dementia with Lewy bodies (DLB) and dry age-related macular degeneration (dry AMD). We believe CT1812 and our pipeline of σ-2 receptor modulators can regulate pathways that are impaired in these diseases. WebApr 13, 2024 · View Atlanta obituaries on Legacy, the most timely and comprehensive collection of local obituaries for Atlanta, Georgia, updated regularly throughout the day …
Discovery of Investigational Drug CT1812, an Antagonist of the …
WebAug 9, 2024 · Discovery of Investigational Drug CT1812, an Antagonist of the Sigma-2 Receptor Complex for Alzheimer's Disease Discovery of Investigational Drug CT1812, an Antagonist of the Sigma-2 Receptor Complex for Alzheimer's Disease ACS Med Chem Lett. 2024 Aug 9;12 (9):1389-1395. doi: 10.1021/acsmedchemlett.1c00048. eCollection 2024 … WebMar 15, 2024 · Cognition Therapeutics announced today its Investigational New Drug (IND) application for the investigation of CT1812 for geographic atrophy (GA) secondary to dry … high seal scunthorpe
Dry Age-Related Macular Degeneration - Cognition …
WebCT1812 was found to be safe and well tolerated in a double-blind, placebo-controlled Phase 1b/2 study in 19 patients with mild to moderate Alzheimer’s disease. In this study, treatment with CT1812 was also associated with positive changes in synaptic proteins that are considered important for normal synaptic function. Based on these results ... WebMar 30, 2024 · CT1812 is also currently being assessed in the phase 2 SHIMMER trial (NCT0522514), which had patient dosing commence in July 2024. 4 The double-blind, placebo-controlled, randomized trial is expected to enroll 120 adults aged 50 to 80 years old with DLB to be assigned to either placebo or 1 of 2 daily doses of CT1812 for 6 months. WebApr 25, 2024 · This Phase 2 study is designed to evaluate the safety of two doses of CT1812 administered once daily for 6 months in adults aged 50 to 85 who have been … how many daughter cells meiosis 1 and 2